Vishay Intertechnology Inc.

VSH

NYSE; business equipment; SIC 3670, Electronic Components & Accessories; CIK 0000103730

D

fourth fifth of 496 graded peers in business equipment

rank 371 of 496; percentile 74.7; sampling error 2.2 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	D percentile 70.4
Solvency	B/C percentile 41.5
Growth and financing	D percentile 65.4
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $4.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress
Inputs computable	8 of 14
Graded from	filings received through Feb 13, 2026 251 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$29.89 2026-10-21; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

Vishay Intertechnology, Inc. ("Vishay," the "Company," "we," "us," or "our") manufactures one of the world's largest portfolios of discrete semiconductors and passive electronic components that support innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and healthcare markets. Serving customers worldwide, Vishay brands itself as The DNA of tech.® Semiconductors include MOSFETs, diodes, and optoelectronic components. Passive components include resistors, inductors, and capacitors.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 70.4						
Gross profitability	14.0%	28.6%		75.0	556	2025-12-31
Return on invested capital	not computable	11.2%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(4.6%)	(7.3%)		67.3	616	2025-12-31
Gross margin stability, five years	4.3 pts	2.3 pts		68.9	426	2025-12-31
Solvency, sleeve percentile 41.5						
Twelve-month failure probability	not computable	0.05%				
liabilities and a nearby cover-page share count are required at 2026-07-04						
Altman Z double-prime	3.61	2.15		31.3	563	2025-12-31
Net debt to EBITDA	1.55x	1.11x		56.8	147	2025-12-31
Interest coverage	not computable	3.77x				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.62x	2.01x		36.3	660	2025-12-31
Growth and financing, sleeve percentile 65.4						
Revenue growth, three-year compound	(4.3%)	6.4%		78.3	536	2025-12-31
Free cash flow growth, three-year compound	not computable	18.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	14.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	3.1%	5.0%		52.5	561	2025-12-31
Net share issuance, one year	not computable	0.5%				
two annual share counts are required; found 1						

Among 496 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
366	Gen Digital Inc. (GEN)	73.8	D	
367	Gen Digital Inc. (GENVR)	73.8	D	
368	Phunware, Inc. (PHUN)	74.1	D	fortress balance sheet
369	Take TWO Interactive Software Inc. (TTWO)	74.3	D	
370	Bumble Inc. (BMBL)	74.5	D	
371	Vishay Intertechnology Inc. (VSH)	74.7	D	
372	Bio-Rad Laboratories, Inc. (BIO)	75.1	D	
373	Bio-Rad Laboratories, Inc. (BIO-B)	75.1	D	
374	L3Harris Technologies, Inc. (LHX)	75.4	D	
375	EverCommerce Inc. (EVCM)	75.6	D	
376	Coherent Corp. (COHR)	75.8	D	dilution

What the price implies

at the 2026-10-21 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	101.1%	2.2%	91
Distance from 52-week high	(54.0%)	(30.2%)	25
EBIT to enterprise value	not computable	1.5%	
Free cash flow yield	not computable	2.7%	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	not computable	0.25	
Sales to price	not computable	0.32	
Composite equity issuance, five years	not computable	4.2%	
Relative strength against the sector, log excess return	0.42	(0.26)	91

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.3B
Operating cash flow, four quarters	$346.0M
Months of runway	not finite
Days since last periodic filing	78 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$112.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$594.9M	2025-12-31	2026-02-13	10-K	26-000019
2	assets	us-gaap:Assets	$4.2B	2025-12-31	2026-02-13	10-K	26-000019
3	operating income	us-gaap:OperatingIncomeLoss	$56.9M	2025-12-31	2026-02-13	10-K	26-000019
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$25.5M	2025-12-31	2026-02-13	10-K	26-000019
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$34.5M	2025-12-31	2026-02-13	10-K	26-000019
6	total debt	us-gaap:LongTermDebt	$950.9M	2025-12-31	2026-02-13	10-K	26-000019
7	book equity	us-gaap:StockholdersEquity	$2.1B	2025-12-31	2026-02-13	10-K	26-000019
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$515.0M	2025-12-31	2026-02-13	10-K	26-000019
9	total debt	us-gaap:LongTermDebt	$905.0M	2024-12-31	2026-02-13	10-K	26-000019
10	book equity	us-gaap:StockholdersEquity	$2.0B	2024-12-31	2026-02-13	10-K	26-000019
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$590.3M	2024-12-31	2026-02-13	10-K	26-000019
12	net income	us-gaap:NetIncomeLoss	-$9.0M	2025-12-31	2026-02-13	10-K	26-000019
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$184.3M	2025-12-31	2026-02-13	10-K	26-000019
14	assets	us-gaap:Assets	$4.1B	2024-12-31	2026-02-13	10-K	26-000019
15	revenue	us-gaap:Revenues	$3.1B	2025-12-31	2026-02-13	10-K	26-000019
16	gross profit	us-gaap:GrossProfit	$626.3M	2024-12-31	2026-02-13	10-K	26-000019
17	revenue	us-gaap:Revenues	$2.9B	2024-12-31	2026-02-13	10-K	26-000019
18	gross profit	us-gaap:GrossProfit	$974.5M	2023-12-31	2026-02-13	10-K	26-000019
19	revenue	us-gaap:Revenues	$3.4B	2023-12-31	2026-02-13	10-K	26-000019
20	gross profit	us-gaap:GrossProfit	$1.1B	2022-12-31	2025-02-14	10-K	25-000017
21	revenue	us-gaap:Revenues	$3.5B	2022-12-31	2025-02-14	10-K	25-000017
22	gross profit	us-gaap:GrossProfit	$887.9M	2021-12-31	2024-02-16	10-K	24-000034
23	revenue	us-gaap:Revenues	$3.2B	2021-12-31	2024-02-16	10-K	24-000034
24	current assets	us-gaap:AssetsCurrent	$1.9B	2025-12-31	2026-02-13	10-K	26-000019
25	current liabilities	us-gaap:LiabilitiesCurrent	$720.4M	2025-12-31	2026-02-13	10-K	26-000019
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$892.2M	2025-12-31	2026-02-13	10-K	26-000019

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	liabilities	us-gaap:Liabilities	$2.1B	2025-12-31	2026-02-13	10-K	26-000019
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$224.7M	2025-12-31	2026-02-13	10-K	26-000019
29	operating income	us-gaap:OperatingIncomeLoss	$486.1M	2023-12-31	2026-02-13	10-K	26-000019
30	interest expense	us-gaap:InterestExpense	$25.1M	2023-12-31	2024-02-16	10-K	24-000034
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$273.3M	2025-12-31	2026-02-13	10-K	26-000019
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$173.7M	2024-12-31	2026-02-13	10-K	26-000019
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$320.1M	2024-12-31	2026-02-13	10-K	26-000019
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$365.7M	2023-12-31	2026-02-13	10-K	26-000019
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$329.4M	2023-12-31	2026-02-13	10-K	26-000019
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$484.3M	2022-12-31	2025-02-14	10-K	25-000017
37	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$325.3M	2022-12-31	2025-02-14	10-K	25-000017
38	current assets	us-gaap:AssetsCurrent	$1.9B	2024-12-31	2026-02-13	10-K	26-000019
39	current liabilities	us-gaap:LiabilitiesCurrent	$708.3M	2024-12-31	2026-02-13	10-K	26-000019
40	assets	us-gaap:Assets	$4.2B	2023-12-31	2026-02-13	10-K	26-000019
41	assets	us-gaap:Assets	$3.9B	2022-12-31	2025-02-14	10-K	25-000017
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	150,916,175	2011-02-24	2011-02-25	10-K	11-000309

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.